5.44
0.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lionco Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 603669.SS. It has been listed since 28 May 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥322.5m and a net loss of CN¥193.2m. At that date it held total assets of CN¥1.11bn and shareholders' equity of CN¥620.3m.
Lionco Pharmaceutical Group Co., Ltd. engages in the sale of chemical drug and antibiotic agents. The company is headquartered in Shannan, Xizang. The company went IPO on 2015-05-28. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The firm's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The firm operates its business in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 May 2015
- Employees
- 497
- Website
- lingkang.com.cn ↗
Leadership
Pay as last reported
- Ms. Lingping TaoChairman of the Board, General Manager, since 2012CN¥660,000
- Mr. Hui ZhangVice Chairman of the Board, since 2012
- Mr. Junke ZhangChief Financial OfficerCN¥400,000
- Mr. Guoping SuiDeputy General Manager, Secretary of the Board
- Mr. Liming LiuDeputy General Manager, Director, since 2024
- Mr. Xiaogang TaoDeputy General Manager, Director, since 2015CN¥520,000
- Mr. Hongsheng WangDeputy General ManagerCN¥385,000
- Mr. Chao HeIndependent DirectorCN¥120,000
- Ms. Qian HeIndependent Director
- Mr. Ziqiang PanIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lionco Pharmaceutical Group Co Ltd employs 497 full-time employees in Shannan, Xizang.
- The company focuses on parenteral nutrition agents like Glutamine for injection.
- Lionco's anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection.
Weaknesses
- Lionco Pharmaceutical Group Co Ltd operates solely in the domestic market of China.
- The company's business is limited to chemical prescription medicine production and sales.
- Lionco has no international presence beyond China's domestic market.
Opportunities
- Lionco can expand its parenteral nutrition agents market in China's domestic market.
- The firm's anti-infectious agents could grow with increasing healthcare demand in China.
- Lionco's digestive system agents like Omeprazole Sodium for injection have market potential.
Threats
- Lionco faces competition from other domestic pharmaceutical companies in China.
- The domestic market may have limited growth potential compared to global markets.
- Regulatory changes in China's pharmaceutical sector could impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.